Regardless, some in vitro measures clearly demonstrate a lack of potent WT inhibitory activity of STX-478, as demonstrated in insulin-mediated glucose uptake in primary human adipocytes and in the Broad Institute's PRISM cell viability panel screen, which can be viewed as a population-based model of cancer therapeutic response in which STX-478 demonstrated selective inhibition of kinase- and helical-domain mutant PI3Kα tumor cell lines compared with WT. The gene discussed is INS; the disease is neoplasm.